ArticleJournal of experimental & clinical cancer research : CR2023

Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.

Evangelos Pavlakis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.